Gastrointestinal Compounding Risk

The Gastrointestinal Compounding Risk refers to a critical formulation paradox in the beverage industry’s attempt to cater to users of glp-1-medications.

As traditional alcohol brands and producers of adult soft drinks redesign their Ready-To-Drink (RTD) portfolios to appeal to GLP-1 users, they are aggressively removing traditional carbohydrates and sugars to lower caloric intake and prevent insulin spikes. To maintain taste-parity, formulators frequently substitute these sugars with sugar alcohols (polyols) such as erythritol and xylitol.

However, high doses of sugar alcohols are known to cause digestive distress, including bloating, gas, and diarrhea. Because GLP-1 therapies inherently cause delayed gastric emptying and nausea as primary side effects, RTDs formulated with high levels of sugar alcohols can unintentionally compound severe gastrointestinal discomfort for these specific consumers.

This creates a strategic tension: in the pursuit of metabolic alignment and low-calorie appeal, beverage brands risk accidentally formulating products that make their target demographic physically sick, thereby alienating the exact consumer base they are trying to capture. To mitigate this, brands are increasingly experimenting with alternative rare sugars like allulose, lowering carbonation levels to reduce bloating, and shrinking portion sizes to 8oz or 12oz cans to accommodate reduced gastric capacity.